Teva suspected of fending off competition with Copaxone –

Teva suspected of fending off competition with Copaxone –


  • This is what the European Commission says in an interim report Teva Pharmaceutical Industries Ltd TEWA Violating European Union (EU) antitrust rules over practices that delay competition from multiple sclerosis drug Copaxone.
  • “Effective protection of intellectual property is the key to this scientific advance. We are concerned that Teva may have abused the patent system to protect itself from competitors reported citing the Commission’s head of competition policy, Margrethe Vestager.
  • See also: Teva will begin resolving opioid lawsuits nationwide next year.
  • Between October 2019 and March 2021, the Commission conducted unannounced inspections at the premises of several Teva subsidiaries over their Copaxone-related practices.
  • Suppose the preliminary views of the European Commission are confirmed. In this case, Teva’s behavior violates Article 102 of the Treaty on the Functioning of the European Union, which prohibits abuse of a dominant position.
  • Price promotion: TEVA shares traded 0.59% lower at $8.41 in premarket trading on Monday.

Read full story here

More to explorer

Understanding Key Factors in Accidents

Pedestrian Safety Statistics Pedestrian safety is an urgent concern worldwide, with over 1.3 million people dying in traffic accidents annually. Pedestrians account